19:40 , Jun 4, 2019 |  BC Extra  |  Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
22:38 , Nov 1, 2018 |  BC Extra  |  Company News

Management tracks: CuraSen names Vargas CMO; plus Sosei, Casebia

Neurodegenerative disease start-up CuraSen Therapeutics Inc. (San Mateo, Calif.) hired Gabriel Vargas as its first CMO. Vargas led early development of migraine prophylactic Aimovig erenumab at Amgen Inc. (NASDAQ:AMGN), where he was most recently executive...
23:07 , Jun 5, 2018 |  BC Extra  |  Company News

Management tracks: Sarepta, Gilead

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Financial News

Evolva Holding completes private placement

Evolva Holding S.A. (SIX:EVE), Reinach, Switzerland   Business: Renal, Infectious, Combinatorial biology   Date completed: 3/20/13   Type: Private placement   Raised: CHF16.8 million ($17.8 million)   Shares: 28 million   Price: CHF0.60   Advisor:...
07:00 , Mar 25, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Almirall S.A. (Madrid:ALM) was off €0.10 to €10.08 last week on a double dose of negative news in Germany. The country's Federal Joint Committee (G-BA) said Bretaris/Eklira Genuiar aclidinium bromide has "no additional...
00:15 , Mar 21, 2013 |  BC Extra  |  Financial News

Evolva raises CHF31.3 million

Evolva Holding S.A. (SIX:EVE) raised CHF31.3 million ($33.2 million) through a rights offering and subsequent private placement. Evolva raised CHF14.5 million ($15.4 million) through the sale of 24.2 million shares at CHF0.60 to existing shareholders,...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Evolva Holding, Cargill deal

Evolva and Cargill partnered to develop and commercialize fermentation-derived steviol glycosides. Steviol glycosides are extracted from the leaves of agriculturally grown Stevia rebaudiana and are used as a sweetener. Evolva said it would be the...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

Amyris management update

Amyris Inc. (NASDAQ:AMRS), Emeryville, Calif.   Business: Biomanufacturing   Hired: Zanna McFerson as CBO, effective March 4, formerly VP at Cargill Inc.  ...
07:00 , May 31, 2010 |  BioCentury  |  Regulation

Cutting the VAT

The potential for Egrifta tesamorelin from Theratechnologies Inc. to improve quality of life in HIV patients with lipodystrophy was enough to sway an FDA panel that the candidate warrants approval despite a lack of evidence...
07:00 , Mar 26, 2007 |  BioCentury  |  Finance

Ebb & Flow

The first quarter is already the biggest on record for European biotech fundraising, pushed by a handful of giant deals. With a week to go, $2.6 billion has been raised, beating the prior high of...